Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
University of Texas Southwestern Medical Center
Summary
The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Adults aged 18-65 with confirmed psoriatic arthritis based on CASPAR criteria. * Ability to provide informed consent and comply with study procedures. * Patients with plaque psoriasis BSA\>3% OR PsA with \[SJC\>2 AND TJC \>3\] despite stable background anti-TNF therapy for at least 6 months, with or without csDMARDs (i.e MTX, leflunomide, sulfasalazine, hydroxychloroquine). * Concurrent use of 1 csDMARD, and/or NSAID, and/or oral glucocorticoid is permitted but not required during the study. If such treatment was administered, then participants must meet the follo…
Interventions
- DrugDeucravacitinib
Drug will be administered in tablet form.
- DrugPlacebo
Drug will be administered in tablet form.
Location
- UT Southwestern Medical CenterDallas, Texas